Pharmaids Pharmaceuticals Ltd (PHARMAID) — shareholding pattern, promoter holding, financials and share price
About Pharmaids Pharmaceuticals Ltd (PHARMAID)
Pharmaids Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as PHARMAID and on the BSE under scrip code 524572. Its ISIN is INE117D01018.
Incorporated in 1989, Pharmaids Pharmaceuticals Ltd operates in research, development, and manufacturing services. It is undergoing a business transition and aims to build a CRDMO platform. [1]
Pharmaids Pharmaceuticals Limited, established in Hyderabad, is a supplier of quality-grade speciality chemicals, skin care, hospital care, and generic pharmaceutical products covering orthopedic, neuro, and gastro areas.
The company is involved in manufacturing generics and bulk drugs in diverse forms, including tablets, capsules, liquids, and powders across allopathic, Ayurvedic, and herbal formulations.
Listed peers in Pharmaceuticals: Bal Pharma Ltd, Lactose (India) Ltd, Tyche Industries Ltd, Godavari Drugs Ltd, Krebs Biochemicals & Industries Ltd, Sotac Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹35 a share on 10 Jul 2026, Pharmaids Pharmaceuticals Ltd (PHARMAID) was valued at a price-to-earnings ratio of -10.53x against an industry P/E of 36.41x and a price-to-book of 2.08x on a book value of ₹16.82 per share as of Mar 2025. Solomo computes return on equity of -19.52% and return on capital employed of -12.88% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -10.53x
- Industry P/E
- 36.41x
- P/B
- 2.08x
- EPS (TTM)
- ₹-3.28
- Book value / share
- ₹16.82
- ROE
- -19.52%
- ROCE
- -12.88%
- ROA
- -9.66%
- Debt / equity
- 0.66x
- Dividend yield
- 0%
- EBITDA margin
- -38.7%
- 52-week range
- ₹25.6 – ₹70
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Pharmaids Pharmaceuticals Ltd (PHARMAID) reported revenue of ₹28 crore, net profit of ₹-12 crore and earnings per share of ₹-3.32. That compares with revenue of ₹19 crore and net profit of ₹-14 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹7.18 crore and net profit ₹-1.09 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 4 | 0 | 15 | 19 | 28 |
| Net profit (₹ cr) | 0 | -8 | -12 | -14 | -12 |
| EPS (₹) | 0.15 | -3.52 | -2.26 | -3.06 | -3.32 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 3.72% | - | -15.93% | 28.72% |
| Profit growth | - | - | - | -14.10% |
| Stock price CAGR | 28% | 16% | -10% | -50% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 32.99% of Pharmaids Pharmaceuticals Ltd (PHARMAID) (unchanged from the previous quarter). Market capitalisation was ₹123 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2003.
Largest disclosed public shareholders in Jun 2026: SHREEDHARA SHETTY 14.53%, GOKARAM RAMKRISHNA BALAJI 7.99%, SMITHA SHETTY SACHIT SHETTY 7.72%, VENKATA RAO SADHANALA 4.32%, MAKAM SREEVALLI 2.21%, VENU MADHAVA KAPARTHY 2.03%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 32.99% | - | - | - | 67.01% |
| Mar 2026 | 32.99% | - | - | - | 67.01% |
| Dec 2025 | 32.99% | - | - | - | 67.01% |
| Sep 2025 | 32.99% | - | - | - | 67.01% |
| Jun 2025 | 5.14% | - | - | - | 94.86% |
| Mar 2025 | 5.22% | - | - | - | 94.78% |
| Dec 2024 | 5.22% | - | - | - | 94.78% |
| Sep 2024 | 5.19% | - | - | - | 94.81% |